Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

Glucosinolates (GLs) are phytocompounds mainly found in the Cruciferae (Brassicacea) and Moringa oleifera plants. The hydrolysis of GLs by myrosinase led to the production of isothiocyanate (ITCs). ITCs consumption was associated with different health promoting effects, including to neuroprotective, anti-oxidant and anti-inflammatory capacities. In particular, they showed neuroprotective effects in experimental models of neurodegenerative diseases, including multiple sclerosis (MS) and Parkinson's disease (PD). From different GLs, different ITCs are originated. In particular, from glucoraphanin (GRA) the ITC sulforaphane (SFN) is obtained. The PI of the project is one of the proprietor of a patent (EP2908850B1) for the application of (Rs)-GRA with myrosinase in a buffered solution for the treatment of neurodegenerative diseases. The aim of this project is to evaluate the effects of the administration of bioactivated GRA in different cohorts of adult patients, affected by MS and PD, but also a cohort of pediatric patients affected by neuromuscolar and degenerative diseases. The effects of bioactivated (Rs)-GRA administration will be evaluated with a combination of clinical evaluations and a multiomic (metabolomic, genomic) approach.

NCT Number	NCT07360977
Lead Sponsor	IRCCS Centro Neurolesi Bonino Pulejo Collaborators: Fondazione Edmund Mach, Vittore Buzzi Children's Hospital, Azienda Sanitaria Provinciale Ragusa
Conditions	PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting, Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases
Enrollment	300 participants
Start Date	2026-01
Primary Completion	2026-05-19 (estimated)
Study Completion	2026-05-19 (estimated)
Updated on ClinicalTrials.gov	2026-01-22